Programmed Death Ligand 1 Expression in Laryngeal Squamous Cell Carcinomas and Prognosis.

IF 1.9 Q3 PATHOLOGY
Clinical Pathology Pub Date : 2020-11-12 eCollection Date: 2020-01-01 DOI:10.1177/2632010X20964846
Sebnem Batur, Zeynep Ecem Kain, Emine Deniz Gozen, Nuray Kepil, Ovgu Aydin, Nil Comunoglu
{"title":"Programmed Death Ligand 1 Expression in Laryngeal Squamous Cell Carcinomas and Prognosis.","authors":"Sebnem Batur,&nbsp;Zeynep Ecem Kain,&nbsp;Emine Deniz Gozen,&nbsp;Nuray Kepil,&nbsp;Ovgu Aydin,&nbsp;Nil Comunoglu","doi":"10.1177/2632010X20964846","DOIUrl":null,"url":null,"abstract":"<p><strong>Aim: </strong>We aimed to show the immunohistochemical expression of programmed death ligand 1 (PD-L1) in laryngeal squamous cell carcinomas (SCCs).</p><p><strong>Materials and methods: </strong>The study includes 52 laryngeal SCC cases that underwent surgical resection. Immunohistochemical staining of PD-L1 (Clone 22C3) was applied to the sections obtained from paraffin blocks. Combined Positive Score (CPS) was evaluated as described in manuals. Tumor Proportion Score (TPS) was assessed by the percentage of positive tumor cells which were designated as positive if ⩾1% of the tumor cells showed membranous staining.</p><p><strong>Results: </strong>There were 35 cases (67.3%) having CPS < 1 and 17 cases (32.7%) having CPS ⩾ 1. There was no relationship between CPS, TPS, and the clinicopathological data.</p><p><strong>Conclusion: </strong>Further studies with a large number of advanced-stage cases are needed.</p>","PeriodicalId":53204,"journal":{"name":"Clinical Pathology","volume":"13 ","pages":"2632010X20964846"},"PeriodicalIF":1.9000,"publicationDate":"2020-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/2632010X20964846","citationCount":"5","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Pathology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/2632010X20964846","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2020/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"PATHOLOGY","Score":null,"Total":0}
引用次数: 5

Abstract

Aim: We aimed to show the immunohistochemical expression of programmed death ligand 1 (PD-L1) in laryngeal squamous cell carcinomas (SCCs).

Materials and methods: The study includes 52 laryngeal SCC cases that underwent surgical resection. Immunohistochemical staining of PD-L1 (Clone 22C3) was applied to the sections obtained from paraffin blocks. Combined Positive Score (CPS) was evaluated as described in manuals. Tumor Proportion Score (TPS) was assessed by the percentage of positive tumor cells which were designated as positive if ⩾1% of the tumor cells showed membranous staining.

Results: There were 35 cases (67.3%) having CPS < 1 and 17 cases (32.7%) having CPS ⩾ 1. There was no relationship between CPS, TPS, and the clinicopathological data.

Conclusion: Further studies with a large number of advanced-stage cases are needed.

Abstract Image

Abstract Image

Abstract Image

程序性死亡配体1在喉鳞癌中的表达及预后。
目的:研究程序性死亡配体1 (PD-L1)在喉部鳞状细胞癌(SCCs)中的免疫组织化学表达。材料和方法:本研究包括52例手术切除的喉部鳞状细胞癌病例。对石蜡切片进行PD-L1(克隆22C3)免疫组化染色。综合阳性评分(CPS)按照手册中的描述进行评估。肿瘤比例评分(TPS)通过阳性肿瘤细胞的百分比进行评估,如果肿瘤细胞的小于或等于1%显示膜性染色,则阳性肿瘤细胞的百分比被指定为阳性。结果:有35例(67.3%)发生了CPS。结论:需要对大量晚期病例进行进一步的研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Clinical Pathology
Clinical Pathology PATHOLOGY-
CiteScore
2.20
自引率
7.70%
发文量
66
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信